A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Degenerative Osteoarthritis

Interventions

BIOLOGICAL

TG-C

2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.

BIOLOGICAL

Placebo Control

2 mL normal saline injection